🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "major milestone" in the effort against drug-resistant strains of the bacteria, according to researchers.

A Worldwide Challenge

Gonorrhoea infections are escalating globally, with estimates suggesting over 82 million instances annually. Particularly high rates are observed in Africa and nations within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. In England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely step in the face of rising global incidence, escalating drug resistance and the extremely scarce therapeutic options at this time.”

Health officials are deeply concerned about the surge in treatment-resistant strains. The WHO has designated it as a "critical concern". Ongoing monitoring revealed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Receive Clearance

Zoliflodacin, alternatively called Nuzolvence, was approved by the American regulatory agency in mid-December for treating gonorrhoea. This infection can lead to significant complications, including infertility. Experts hope that specific application of this new drug will help hinder the development of resistance.

Another new antibiotic, created by the pharmaceutical company GSK, was also approved in the same week. This treatment, which is also used to treat UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This approval represents a significant shift in the management of highly resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Clinical Trial Results and Worldwide Availability

Based on findings detailed in a prominent scientific publication, zoliflodacin eradicated the vast majority of uncomplicated infections. This establishes an comparable level with the typical regimen, which involves an injection and a pill. The study included hundreds of participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the ability to make available and distribute the drug in numerous low-income and middle-income countries.

Clinicians treating patients have shared positive views. Having a single-dose, oral treatment of this kind is seen as a "revolutionary step" for managing the epidemic. This is deemed essential to reduce the burden of the disease for patients and to prevent the spread of highly drug-resistant gonorrhoea globally.